We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

146 hedge funds and large institutions have $79.3M invested in Nektar Therapeutics in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 27 increasing their positions, 49 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

509% more call options, than puts

Call options by funds: $329K | Put options by funds: $54K

1.23% less ownership

Funds ownership: 6.08% → 4.86% (-1.2%)

25% less funds holding

Funds holding: 194 → 146 (-48)

35% less capital invested

Capital invested by funds: $121M → $79.3M (-$41.8M)

45% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 49

67% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 72

Holders
146
Holders Change
-48
Holders Change %
-24.74%
% of All Funds
2.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
27
Reduced
49
Closed
72
Calls
$329K
Puts
$54K
Net Calls
+$275K
Net Calls Change
-$182K

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$11.5M
2
MAM
Monaco Asset Management
Monaco
+$6.58M
3
SCM
Sio Capital Management
New York
+$4.97M
4
Citadel Advisors
Citadel Advisors
Florida
+$4.86M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.16M

Top Sellers

1
Invesco
Invesco
Georgia
-$22.7M
2
BlackRock
BlackRock
New York
-$19.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.44M
4
State Street
State Street
Massachusetts
-$4.45M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$10.3M +$11.5M +1,082,014 +931%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.93M -$5.44M -510,150 -39%
Citadel Advisors
3
Citadel Advisors
Florida
$5.58M +$4.86M +456,039 +239%
MAM
4
Monaco Asset Management
Monaco
$5.33M +$6.58M +617,381 New
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$5.26M +$4.16M +390,044 +177%
BlackRock
6
BlackRock
New York
$4.95M -$19.2M -1,796,976 -76%
Primecap Management
7
Primecap Management
California
$4.69M -$2.37M -222,210 -29%
SCM
8
Sio Capital Management
New York
$4.02M +$4.97M +466,359 New
Invesco
9
Invesco
Georgia
$3.18M -$22.7M -2,129,810 -85%
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$2.8M +$1.6M +150,160 +86%
Millennium Management
11
Millennium Management
New York
$2.57M +$3.14M +294,305 +7,848%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$2.53M +$2.68M +251,051 +597%
Renaissance Technologies
13
Renaissance Technologies
New York
$2.35M +$773K +72,533 +36%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$2.19M +$895K +83,946 +49%
Two Sigma Investments
15
Two Sigma Investments
New York
$1.84M +$836K +78,359 +58%
AQR Capital Management
16
AQR Capital Management
Connecticut
$1.62M +$59.4K +5,573 +3%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$1.2M +$1.01M +94,468 +214%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.09M -$1.15M -108,140 -46%
Morgan Stanley
19
Morgan Stanley
New York
$905K -$195K -18,254 -15%
Goldman Sachs
20
Goldman Sachs
New York
$749K +$178K +16,690 +24%
Charles Schwab
21
Charles Schwab
California
$575K -$145K -13,562 -17%
Squarepoint
22
Squarepoint
New York
$469K +$95.5K +8,952 +20%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$465K -$907K -85,027 -61%
Jane Street
24
Jane Street
New York
$450K +$185K +17,336 +50%
CM
25
CM Management
Florida
$431K +$249K +23,333 +87%
1
2 3 4 5

NKTR Hedge Fund Activity: Q2 2023 in Review

146 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2023, worth a combined $79.3M — down 35% from $121M a quarter earlier.

Sellers outnumbered buyers: 72 funds closed out of NKTR and 24 opened new positions — a net loss of 48 holders — while 49 trimmed existing stakes and 27 added.

The largest buyer was Deep Track Capital, adding an estimated $11.5M. The largest seller was Invesco, cutting an estimated $22.7M.

  • 146 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2023, down from 194 in Q1 2023.
  • Funds reported $79.3M of Nektar Therapeutics stock for Q2 2023, down 35% quarter-over-quarter.
  • 24 funds opened new Nektar Therapeutics positions in Q2 2023 and 72 closed out, a net change of -48 holders.
  • The largest Nektar Therapeutics buyer in Q2 2023 was Deep Track Capital, an estimated $11.5M added.
  • The largest Nektar Therapeutics seller in Q2 2023 was Invesco, an estimated $22.7M sold.

Based on aggregated 13F filings for Q2 2023.